Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

BCR-ABL-negative chronic myeloid leukemia.

Sonja Burgstaller1, Andreas Reiter, Nicholas C P Cross

  • 1Wessex Regional Genetics Laboratory, University of Southampton,Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK.

Current Hematologic Malignancy Reports
|April 29, 2010
PubMed
Summary

Constitutive activation of protein tyrosine kinases drives myeloproliferative disorders. Accurate diagnosis and molecular findings are crucial for targeted signal transduction therapy and disease classification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Frontiers in immunology·2026
Same author

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026
Same author

Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.

European journal of haematology·2026
Same author

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026
Same author

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Constitutive activation of protein tyrosine kinases is central to myeloproliferative disorders (MPDs).
  • BCR-ABL-negative chronic myeloid leukemia (CML) is a rare, heterogeneous MPD.
  • Understanding causative mutations is key to disease pathogenesis.

Purpose of the Study:

  • To elucidate the full spectrum of causative mutations in BCR-ABL-negative CML.
  • To highlight the importance of accurate diagnosis for individualized treatment.
  • To emphasize the need for incorporating new molecular findings into disease classification.

Main Methods:

  • Morphological analysis
  • Karyotyping
  • Molecular genetics

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Main Results:

  • Activated tyrosine kinases represent viable targets for signal transduction therapy.
  • Accurate diagnostic methods are essential for directing patient treatment.
  • New molecular discoveries are vital for refining disease classification.

Conclusions:

  • Targeted therapies for MPDs require precise molecular diagnosis.
  • Advancements in molecular genetics are critical for personalized medicine in CML.
  • Integrating novel molecular findings will improve MPD classification systems.